Zacks Research Has Bearish Outlook for BIO FY2025 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Analysts at Zacks Research cut their FY2025 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $9.98 for the year, down from their previous forecast of $10.02. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2026 earnings at $2.60 EPS, Q1 2027 earnings at $2.12 EPS and Q2 2027 earnings at $2.44 EPS.

Several other equities research analysts have also recently commented on the company. Citigroup boosted their price target on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Royal Bank Of Canada increased their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Wells Fargo & Company raised their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings cut Bio-Rad Laboratories from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Thursday, November 13th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $304.85 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of -12.54 and a beta of 1.04. The business’s 50-day moving average is $303.62 and its 200-day moving average is $271.46. Bio-Rad Laboratories has a fifty-two week low of $211.43 and a fifty-two week high of $373.69.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The firm had revenue of $653.00 million during the quarter, compared to analyst estimates of $651.30 million. During the same period in the prior year, the business posted $2.01 EPS. The company’s revenue for the quarter was up .5% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Institutional Trading of Bio-Rad Laboratories

Hedge funds have recently modified their holdings of the company. Quent Capital LLC acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $25,000. Farther Finance Advisors LLC raised its position in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares in the last quarter. Quarry LP bought a new stake in shares of Bio-Rad Laboratories during the first quarter worth $29,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Activity

In related news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $306.18, for a total transaction of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares of the company’s stock, valued at $156,151.80. This trade represents a 57.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 17.06% of the stock is owned by company insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.